logo-loader
Pharmaxis Ltd

Pharmaxis features in APAC’s top 100 most innovative pharma companies report

Pharmaxis was ranked 38 out of the 100 companies named as innovators in the small to medium- sized enterprises category.

Pharmaxis Ltd - Pharmaxis features in APAC’s top 100 most innovative pharma companies report
Pharmaxis is one of 14 Australian companies included in the top 100 and is ranked second of the 14

Pharmaxis Ltd (ASX:PXS) has been included in a new report which ranks the company among the top 100 most innovative pharma companies in the Asia Pacific (APAC) region.

The report was prepared by Cortellis and is entitled “Pharmaceutical innovation in the APAC region”.

It studied a cohort of 929 companies including multi-nationals across 14 countries/regions that have or are developing innovative pharmaceutical products.

Fourteen Australian companies featured in the top-100 and Pharmaxis was the second-highest ranked of the14.

Translating R&D into results

Pharmaxis’ CEO Gary Phillips said: “I’m delighted but not surprised that Pharmaxis has been recognised in this report, the first of its kind.

“We have clearly met key indicators such as being able to demonstrate a strong pipeline and translate our R&D into actual drug candidates.

“Early stage partnering was also a measure studied for the report and Pharmaxis has made this a key business objective.”

Track record of delivering value

The company’s ability to create value for shareholders through R&D is best exemplified by its 2015 deal with Boehringer.

Pharmaxis sold its anti‐inflammatory drug candidate to Boehringer in a deal structured to deliver potential value in excess of $A750 million.

The Pharmaxis drug discovery team has moved four drugs into the clinic over the last five years.

The company’s pipeline is focused on anti‐fibrotic agents to treat a variety of diseases through inhibiting the LOX and LOXL2 enzymes.

The LOXL2 inhibition program is currently in a commercial partnering process.

Quick facts: Pharmaxis Ltd

Price: $0.19

Market: ASX
Market Cap: $73.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19

RNS

Director/PDMR Shareholding

3 days, 12 hours ago

Grant of Share Options

4 days, 11 hours ago

Final Results

5 days, 20 hours ago

Trading Update

on 31/7/19

Board changes

on 12/4/19

2 min read